[6-K] NOVO NORDISK A S Current Report (Foreign Issuer)
Rhea-AI Filing Summary
Novo Nordisk A/S is executing a share repurchase programme as part of an overall plan to buy back up to DKK 15 billion of B shares over a 12‑month period starting 4 February 2026. A specific tranche targets up to DKK 3.8 billion of B shares from 4 February to 4 May 2026.
From 4 February to 20 February 2026, the company repurchased 2,750,000 B shares at an average price of DKK 306.18, for a total of DKK 841,997,435. After these transactions, Novo Nordisk holds 20,139,799 B shares of DKK 0.10 as treasury shares, equal to 0.5% of its 4,465,000,000 total A and B shares.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 23, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 23 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.
Since the announcement 16 February 2026, the following transactions have been made:
Number of B shares |
Average purchase price |
Transaction value, DKK | |
| Accumulated, last announcement | 1,750,000 | 533,796,640 | |
| 16 February 2026 | 200,000 | 307.89 | 61,578,124 |
| 17 February 2026 | 200,000 | 309.73 | 61,945,457 |
| 18 February 2026 | 200,000 | 309.63 | 61,925,026 |
| 19 February 2026 | 200,000 | 309.29 | 61,858,675 |
| 20 February 2026 | 200,000 | 304.47 | 60,893,513 |
| Accumulated under the programme | 2,750,000 | 841,997,435 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 20,139,799 B shares of DKK 0.10 as treasury shares, corresponding to 0.5% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12month period beginning 4 February 2026. As of 20 February 2026, Novo Nordisk has since 4 February 2026 repurchased a total 2,750,000 B shares at an average share price of DKK 306.18 per B share equal to a transaction value of DKK 841,997,435.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown | Liz Skrbkova (US) |
| +45 3079 9289 | +1 609 917 0632 |
| globalmedia@novonordisk.com | lzsk@novonordisk.com |
| Investors: | |
| Michael Novod | Jacob Martin Wiborg Rode |
| +45 3075 6050 | +45 3075 5956 |
| nvno@novonordisk.com | jrde@novonordisk.com |
| Max Ung | Sina Meyer |
| +45 3077 6414 | +45 3079 6656 |
| mxun@novonordisk.com | azey@novonordisk.com |
| Alex Bruce | Christoffer Sho Togo Tullin |
| +45 34 44 26 13 | +45 3079 1471 |
| axeu@novonordisk.com | cftu@novonordisk.com |
| Frederik Taylor Pitter | |
| +1 609 613 0568 | |
| fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 14/ 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 23, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |
